These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26505921)

  • 1. Qualitative and Quantitative Gadoxetic Acid-enhanced MR Imaging Helps Subtype Hepatocellular Adenomas.
    Tse JR; Naini BV; Lu DS; Raman SS
    Radiology; 2016 Apr; 279(1):118-27. PubMed ID: 26505921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?
    Auer TA; Fehrenbach U; Grieser C; Penzkofer T; Geisel D; Schmelzle M; Müller T; Bläker H; Seehofer D; Denecke T
    Eur Radiol; 2020 Jun; 30(6):3497-3506. PubMed ID: 32086574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular Adenoma Subtypes Based on 2017 Classification System: Exploratory Study of Gadoxetate Disodium-Enhanced MRI Features With Proposal of a Diagnostic Algorithm.
    Tse JR; Felker ER; Cao JJ; Naini BV; Liang T; Lu DSK; Raman SS
    AJR Am J Roentgenol; 2023 Apr; 220(4):539-550. PubMed ID: 36169546
    [No Abstract]   [Full Text] [Related]  

  • 4. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
    Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
    Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization.
    Hwang J; Kim YK; Jeong WK; Choi D; Rhim H; Lee WJ
    Radiology; 2015 Jul; 276(1):137-46. PubMed ID: 25734551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtyping of hepatocellular adenomas using Gd-EOB-DTPA: a qualitative and quantitative analysis.
    Schaible J; Schreyer AG; Mehrabi A; Longerich T; Kieser M; Kreimeyer S; Klauss M; Grenacher L
    Acta Radiol; 2023 Jul; 64(7):2253-2260. PubMed ID: 36650712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification.
    van Aalten SM; Thomeer MG; Terkivatan T; Dwarkasing RS; Verheij J; de Man RA; Ijzermans JN
    Radiology; 2011 Oct; 261(1):172-81. PubMed ID: 21875850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging.
    Ba-Ssalamah A; Antunes C; Feier D; Bastati N; Hodge JC; Stift J; Cipriano MA; Wrba F; Trauner M; Herold CJ; Caseiro-Alves F
    Radiology; 2015 Oct; 277(1):104-13. PubMed ID: 25985059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison.
    Cannella R; Brancatelli G; Rangaswamy B; Minervini MI; Borhani AA; Furlan A
    Eur J Radiol; 2019 Oct; 119():108633. PubMed ID: 31437747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification.
    Laumonier H; Bioulac-Sage P; Laurent C; Zucman-Rossi J; Balabaud C; Trillaud H
    Hepatology; 2008 Sep; 48(3):808-18. PubMed ID: 18688875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of MRI features of hepatocyte nuclear factor 1α-inactivated hepatocellular adenoma].
    Pan H; Chen XF; Han J; Ji Y; Zeng MS; Wang ML
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1192-1197. PubMed ID: 38238954
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis.
    Grazioli L; Bondioni MP; Haradome H; Motosugi U; Tinti R; Frittoli B; Gambarini S; Donato F; Colagrande S
    Radiology; 2012 Feb; 262(2):520-9. PubMed ID: 22282184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
    Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
    Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver.
    Holland AE; Hecht EM; Hahn WY; Kim DC; Babb JS; Lee VS; West AB; Krinsky GA
    Radiology; 2005 Dec; 237(3):938-44. PubMed ID: 16306035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
    Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
    Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.
    Kitao A; Zen Y; Matsui O; Gabata T; Kobayashi S; Koda W; Kozaka K; Yoneda N; Yamashita T; Kaneko S; Nakanuma Y
    Radiology; 2010 Sep; 256(3):817-26. PubMed ID: 20663969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.